Published in Br J Cancer Suppl on July 01, 1996
Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br J Cancer (1998) 1.61
An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br J Cancer (1997) 0.98
Characterization of three-dimensional tissue cultures using electrical impedance spectroscopy. Biophys J (1999) 0.88
The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104. Front Oncol (2013) 0.86
Novel in vitro model barriers for evaluation of the permeability of antitumor compounds, thioxanthones. Invest New Drugs (2006) 0.86
Changes in P-glycoprotein activity are mediated by the growth of a tumour cell line as multicellular spheroids. Cancer Cell Int (2005) 0.85
EO9 (Apaziquone): from the clinic to the laboratory and back again. Br J Pharmacol (2013) 0.85
Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib. BMC Cancer (2012) 0.84
Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. Br J Pharmacol (2002) 0.81
Modeling of oxygen transport across tumor multicellular layers. Microvasc Res (2006) 0.80
Development of drug loaded nanoparticles for tumor targeting. Part 2: Enhancement of tumor penetration through receptor mediated transcytosis in 3D tumor models. Nanoscale (2013) 0.79
A microfluidic system for investigation of extravascular transport and cellular uptake of drugs in tumors. Biotechnol Bioeng (2011) 0.79
Improved Methods to Generate Spheroid Cultures from Tumor Cells, Tumor Cells & Fibroblasts or Tumor-Fragments: Microenvironment, Microvesicles and MiRNA. PLoS One (2015) 0.75
A Multilayered Cell Culture Model for Transport Study in Solid Tumors: Evaluation of Tissue Penetration of Polyethyleneimine Based Cationic Micelles. Nano Today (2014) 0.75
Distribution and activity of antineoplastic drugs in a tumor model. J Natl Cancer Inst (1989) 1.49
Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model. J Natl Cancer Inst (1994) 1.14
Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids. Cancer Chemother Pharmacol (1992) 1.13
Two-dimensional diffusion limited system for cell growth. Cell Tissue Kinet (1985) 1.04
Comparison of binding of [3H]misonidazole and [14C]misonidazole in multicell spheroids. Radiat Res (1985) 0.98
NLA-1: a 2-nitroimidazole radiosensitizer targeted to DNA by intercalation. Int J Radiat Oncol Biol Phys (1992) 0.96
Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother Pharmacol (1984) 0.95
Hypoxic fraction and binding of misonidazole in EMT6/Ed multicellular tumor spheroids. Radiat Res (1985) 0.91
Covalent coupling of methotrexate to dextran enhances the penetration of cytotoxicity into a tissue-like matrix. Cancer Res (1994) 0.89
DNA-targeted 2-nitroimidazoles: in vitro and in vivo studies. Br J Cancer (1994) 0.88
Reductive metabolism and hypoxia-selective toxicity of nitracrine. Int J Radiat Oncol Biol Phys (1986) 0.87
Microbiological and clinical evaluation of the isolator lysis-centrifugation blood culture tube. J Clin Microbiol (1983) 5.77
Anaerobic bacteremia. Mayo Clin Proc (1972) 4.79
Optimal testing parameters for blood cultures. Clin Infect Dis (2004) 3.17
The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study. Arch Otolaryngol (1980) 2.93
Prevalence of Helicobacter pylori in specific forms of gastritis. Further evidence supporting a pathogenic role for H. pylori in chronic nonspecific gastritis. Dig Dis Sci (1991) 2.67
Anaerobic bacteremia: decreasing rate over a 15-year period. Rev Infect Dis (1991) 2.65
An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA (1997) 2.52
The antimicrobial removal device. A microbiological and clinical evaluation. Am J Clin Pathol (1982) 2.40
Antimicrobial susceptibilities of species of viridans streptococci. J Infect Dis (1979) 2.37
N-Substituted 2-(2,6-dinitrophenylamino)propanamides: novel prodrugs that release a primary amine via nitroreduction and intramolecular cyclization. J Med Chem (1999) 2.13
Infective endocarditis caused by HACEK microorganisms. Annu Rev Med (1997) 2.03
Prospective evaluation of the risk of bacteremia associated with transesophageal echocardiography. Circulation (1991) 1.99
Ceftriaxone sodium therapy of penicillin G-susceptible streptococcal endocarditis. JAMA (1992) 1.97
Influence of referral bias on the apparent clinical spectrum of infective endocarditis. Am J Med (1990) 1.96
DNA-directed alkylating agents. 6. Synthesis and antitumor activity of DNA minor groove-targeted aniline mustard analogues of pibenzimol (Hoechst 33258) J Med Chem (1994) 1.93
Erythromycin: a microbial and clinical perspective after 30 years of clinical use (2). Mayo Clin Proc (1985) 1.93
G-protein-coupled inwardly rectifying potassium channels are targets of alcohol action. Nat Neurosci (1999) 1.92
Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1). Mayo Clin Proc (1985) 1.91
Selective beta-1 receptor blockade with oral practolol in man. A dose-related phenomenon. J Clin Invest (1975) 1.91
Prosthetic valve endocarditis. Ann Intern Med (1975) 1.78
Correlation of beta blockade with serum practolol levels after oral administration. Clin Pharmacol Ther (1972) 1.74
Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann Intern Med (1984) 1.64
Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents. J Infect Dis (1996) 1.63
Traveling toothpicks. Mayo Clin Proc (1983) 1.61
Analysis of 281,797 consecutive blood cultures performed over an eight-year period: trends in microorganisms isolated and the value of anaerobic culture of blood. Clin Infect Dis (1997) 1.60
Serodiagnosis of Helicobacter pylori: comparison of enzyme-linked immunosorbent assays. J Clin Microbiol (1991) 1.59
Symposium on infective endocarditis. III. Endocarditis due to gram-negative bacteria. Report of 56 cases. Mayo Clin Proc (1982) 1.57
Tracheostomy: a risk factor for mediastinitis after cardiac operation. Ann Thorac Surg (2001) 1.51
Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst (1989) 1.49
Clinical significance of Pseudallescheria boydii: a review of 10 years' experience. Mayo Clin Proc (1985) 1.43
Toxic shock syndrome, a newly recognized disease entity. Report of 11 cases. Mayo Clin Proc (1980) 1.41
Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci. Antimicrob Agents Chemother (1982) 1.41
Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med (1987) 1.40
Short-term therapy for streptococcal infective endocarditis. Combined intramuscular administration of penicillin and streptomycin. JAMA (1981) 1.39
Prosthetic valve endocarditis. Mayo Clin Proc (1982) 1.36
Haemophilus endocarditis. Report of 14 patients. Mayo Clin Proc (1977) 1.35
Tetracyclines, chloramphenicol, erythromycin, and clindamycin. Mayo Clin Proc (1977) 1.34
Developmental changes in speech discrimination in infants. J Speech Hear Res (1977) 1.31
Vancomycin therapy for infective endocarditis. Rev Infect Dis (1982) 1.30
Synergy of penicillin and decreasing concentration of aminoglycosides against enterococci from patients with infective endocarditis. Antimicrob Agents Chemother (1980) 1.29
Treatment of streptococcal infective endocarditis. Am J Med (1985) 1.28
Trabeculectomy with adjunctive mitomycin C in pediatric glaucoma. Am J Ophthalmol (1998) 1.25
Molecular, serological, and clinical features of 16 consecutive cases of invasive streptococcal disease. Southeastern Minnesota Streptococcal Working Group. Clin Infect Dis (1998) 1.24
In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis. Antimicrob Agents Chemother (1987) 1.23
Candida lusitaniae--an opportunistic pathogen. Diagn Microbiol Infect Dis (1985) 1.23
Emboli in infective endocarditis: the prognostic value of echocardiography. Ann Intern Med (1991) 1.23
Pulmonary disease in the immunocompromised host (2). Mayo Clin Proc (1985) 1.21
Aerococcus viridans endocarditis. Mayo Clin Proc (1984) 1.17
Linguistic experience and phonemic perception in infancy: a crosslinguistic study. Child Dev (1979) 1.16
Infective endocarditis--a 25 year overview of diagnosis and therapy. J Am Coll Cardiol (1983) 1.16
Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer (1998) 1.16
Viral and epidemiologic studies of idiopathic sudden hearing loss. Otolaryngol Head Neck Surg (1983) 1.14
Anticoagulant therapy and central nervous system complications in patients with prosthetic valve endocarditis. Circulation (1978) 1.14
Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines. J Med Chem (1990) 1.13
Infective endocarditis. Olmsted County, Minnesota, 1950 through 1981. JAMA (1985) 1.12
Studies of the reputed augmentation of the cardiovascular effects of catecholamines in patients with spontaneous hyperthyroidism. J Pharmacol Exp Ther (1972) 1.12
Visual reinforcement of head-turn responses in infants under 12 months of age. J Speech Hear Disord (1977) 1.11
Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res (1994) 1.11
Leukocyte chemotaxis in diabetic patients and their nondiabetic first-degree relatives. Diabetes (1976) 1.10
Relative efficacies of broad-spectrum cephalosporins for treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis. Antimicrob Agents Chemother (1993) 1.09
Interaction of the antitumor drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines with nucleic acids. Mol Pharmacol (1981) 1.09
Pulmonary disease in the immunocompromised host. 1. Mayo Clin Proc (1985) 1.09
Adverse effects of vancomycin administered in the perioperative period. Mayo Clin Proc (1986) 1.08
Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J Med Chem (1986) 1.07
An immunological assessment of patients with anorexia nervosa. Am J Clin Nutr (1981) 1.07
Management of complications of infective endocarditis. Mayo Clin Proc (1982) 1.06
Ketolide treatment of Haemophilus influenzae experimental pneumonia. Antimicrob Agents Chemother (1999) 1.06
Group B streptococcal infective endocarditis. Arch Intern Med (1985) 1.06
The relationship of idiopathic sudden hearing loss to diabetes mellitus. Laryngoscope (1982) 1.05
Two-vessel coronary artery dissection in the peripartum period. Case report and literature review. Angiology (1994) 1.04
Efficacy of cilofungin therapy administered by continuous intravenous infusion for experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother (1992) 1.04
Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. J Med Chem (1992) 1.04
Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis (2010) 1.04
Infective endocarditis caused by Actinobacillus actinomycetemcomitans: report of four cases. Mayo Clin Proc (1980) 1.03
Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis. Arch Intern Med (1989) 1.03
A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal Biochem (1984) 1.02
Antibiotic treatment of infective endocarditis. Annu Rev Med (1983) 1.02
Clinical significance of postmortem cultures. Arch Pathol (1972) 1.02
Effects of beta-adrenergic receptor blockade in normal subjects before, during, and after triiodothyronine-induced hypermetabolism. J Clin Invest (1966) 1.01
Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. J Med Chem (1993) 1.00
Empiric therapy with moxalactam alone in patients with bacteremia. Mayo Clin Proc (1984) 1.00
Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin Investig Drugs (2000) 1.00
Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev (1993) 0.99
[14C]urea breath test for diagnosis of Helicobacter pylori. Dig Dis Sci (1990) 0.98
Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol (1997) 0.98
Comparison of ciprofloxacin and co-trimoxazole in the treatment of uncomplicated urinary tract infection in women. J Antimicrob Chemother (1986) 0.98
Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin Infect Dis (1998) 0.98
Why treat sudden hearing loss. Am J Otol (1984) 0.98
An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br J Cancer (1997) 0.98
Prospective evaluation of the utility of molecular techniques for diagnosing nosocomial transmission of multidrug-resistant tuberculosis. Mayo Clin Proc (1996) 0.97
Bis(dialkyl)dithiocarbamato cobalt(III) complexes of bidentate nitrogen mustards: synthesis, reduction chemistry and biological evaluation as hypoxia-selective cytotoxins. Anticancer Drug Des (1998) 0.97
NLA-1: a 2-nitroimidazole radiosensitizer targeted to DNA by intercalation. Int J Radiat Oncol Biol Phys (1992) 0.96
Risk factors for infective endocarditis. Infect Dis Clin North Am (1993) 0.96
Cardiorenal hemodynamic effects of ethacrynic acid. Am Heart J (1966) 0.95
Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int J Radiat Oncol Biol Phys (1998) 0.95
Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. Biochem Pharmacol (2009) 0.95
Incidence of bacteremia in adults without infection. J Clin Microbiol (1976) 0.95
Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys (1994) 0.94
Rapid development of bilateral internal carotid artery aneurysm from sphenoid sinus aspergillosis. Skull Base Surg (1998) 0.94
Influence of gentamicin dose size on the efficacies of combinations of gentamicin and penicillin in experimental streptomycin-resistant enterococcal endocarditis. Antimicrob Agents Chemother (1982) 0.94